

10/567056  
IAP9 Rec'd PCT/PTO 01 FEB 2006

Attorney Docket No. Le A 36 764

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Joachim Schuhmacher, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2004/008708

Title: Determination of Free Fractions

**MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY  
37 C.F.R. 1.97(b)(2)**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO]. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

**FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

  
\_\_\_\_\_  
William F. Gray  
Reg. No.: 31,018  
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
Telephone: (203) 812-2712  
Facsimile: (203) 812-6459

10/567056  
IAP9 Rec'd PCT/PTO 01 FEB 2006

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	[to be assigned]
		Filing Date	
		First Named Inventor	Joachim Schuhmacher
		Art Unit	
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	Le A 36 764

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Shee

1

2

Application Number [to be assigned]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	F1	WO 03/010330 A2	02-06-2003	Phares Pharmaceutical	Research N.V.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	[to be assigned]
				<b>Filing Date</b>	
				<b>First Named Inventor</b>	Joachim Schuhmacher
				<b>Art Unit</b>	
				<b>Examiner Name</b>	
Sheet	2	of	2	Attorney Docket Number	Le A 36 764

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	<b>R1</b>	Austin, R. P., et al., "The Influence of Nonspecific Microsomal Binding on Apparent Intrinsic Clearance, and its Prediction from Physicochemical Properties", Drug Metabolism and Disposition, 30(12): 1497-1503 (2002)		T <sup>2</sup>
	<b>R2</b>	Boyd, B. J., et al., "Using the Polymer Partitioning Method to Probe the Thermodynamic Activity of Poorly Water-Soluble Drugs Solubilized in Model Lipid Digestion Products", J. Pharm. Sci., 92(6): 1262-1271 (June 2003)		
	<b>R3</b>	Loidl-Stahlhofen, A., et al., "Multilamellar Liposomes and Solid-Supported Lipid Membranes (TRANSIL): Screening of Lipid-Water Partitioning toward a High-Throughput Scale", Pharm. Res., 18(12): 1782-1788 (2001)		
	<b>R4</b>	Loidl-Stahlhofen, A., et al., "Solid-Supported Lipid Membranes as a Tool for Determination of Membrane Affinity: High-Throughput Screening of a Physicochemical Parameter", J. Pharm. Sci., 90(5): 599-606 (2001)		
	<b>R5</b>	Santos, N. C., et al., "Quantifying molecular partition into model systems of biomembranes: an emphasis on optical spectroscopic methods", Biochimica et Biophysica Acta, 1612: 123-135 (2003)		
	<b>R6</b>	Schuhmacher, J., et al., "Determination of the Free Fraction and Relative Free Fraction of Drugs Strongly Bound to Plasma Proteins", J. Pharm. Sci., 89(8): 1008-1021 (August 2000)		
	<b>R7</b>	Schmitz, A. A. P., et al., "Interactions of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS)-Related Protein with a Novel Solid-Supported Lipid Membrane System (TRANSIL)", Analytical Biochem., 268: 343-353 (1999)		
	<b>R8</b>	Poulin, P., et al., "Prediction of Pharmacokinetics Prior to In Vivo Studies. 1. Mechanism-Based Prediction of Volume of Distribution", J. Pharm. Sci., 91(1): 129-156 (January 2002)		
	<b>R9</b>	Veronese, M. E., et al., "Plasma Protein Binding of Amiodarone in a Patient Population: Measurement by Erythrocyte Partitioning and a Novel Glass-Binding Method", Br. J. Clin. Pharmac., 26: 721-731 (1988)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.